CME Presentations

Nasal Polyps Expert Interview

Presentations

Speakers

  • Eugenio De Corso, MD, PhD

    Eugenio De Corso, MD, PhD

    Eugenio De Corso, MD, PhD

    Ear, Nose, and Throat Specialist

    Eugenio De Corso, MD, PhD is an ear, nose, and throat specialist at the Institute of Otorhinolaryngology, A. Gemelli University Hospital Foundation, Catholic University of the Sacred Heart in Rome, Italy. His principal areas of clinical expertise are nasal polyps, chronic rhinosinusitis, allergic and nonallergic rhinitis, sinusitis, and otitis media. His research interests include endoscopic treatment, laryngectomy, brachytherapy, otosclerosis surgery, type 2 inflammation in nonallergic rhinitis, and the management of patients with chronic rhinosinusitis with nasal polyps (CRSwNP). He has overseen clinical studies of patients undergoing new therapies, such as biologics for severe uncontrolled CRSwNP and the efficacy of biologics on refractory eosinophilic otitis media associated with CRSwNP. He has authored or co-authored more than 100 publications and has reviewed several international journals.

    Session Appearances

    Diagnostic Workup of the Patient with Uncontrolled Severe Nasal Polyps: Proposed Pathway to Determine Candidacy for Biologic Therapy

  • Marco Caminati, MD

    Marco Caminati, MD

    Marco Caminati, MD

    Allergy and Clinical Immunology Specialist

    Marco Caminati, MD is an allergy and clinical immunology specialist, as well as an assistant professor in allergy, clinical immunology, and severe asthma at the University of Verona Asthma Center and Allergy Unit at Verona University Hospital in Verona, Italy. Most of his clinical and scientific activity focuses on asthma, severe asthma, and associated comorbidities, including chronic rhinosinusitis with nasal polyps (CRSwNP), as well as biologics and immunotherapy. His research interests include rare autoimmune disorders with hypereosinophilic syndrome (HES), eosinophilic granulomatosis with polyangiitis (EGPA), and eosinophilic esophagitis (EoE), with a special focus on new targeted therapies. He co-chaired the Junior Members Steering Group of the World Allergy Organization (WAO) and was involved in the European Academy of Allergy and Clinical Immunology (EAACI) Junior Member Assembly.

    Session Appearances

    Diagnostic Workup of the Patient with Uncontrolled Severe Nasal Polyps: Proposed Pathway to Determine Candidacy for Biologic Therapy

CME Information

Global LogoPQH Logo

Diagnostic Workup of the Patient with Uncontrolled Severe Nasal Polyps: Proposed Pathway to Determine Candidacy for Biologic Therapy

This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with Asthma and Allergy Foundation of America (AAFA)

ACKNOWLEDGEMENT

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

DATE OF RELEASE/EXPIRATION

This activity was released on November 14th, 2023 and is valid for 12 months. Requests for credit must be made no later than November 14th, 2024.

TARGET AUDIENCE

The educational design of this activity addresses the needs of ENTs, Allergists, Immunologists, Specialty NPs and PAs.

STATEMENT OF NEED/PROGRAM OVERVIEW

Patients with nasal polyps (NPs) experience a variety of symptoms that negatively impact health-related quality of life (QoL). On the frontlines of care, it is important to be aware of the underlying pathophysiology driven by type 2 (T2) inflammation that leads to NPs and drives recurrent disease and treatment resistance. In addition, as the management of NPs continues to evolve, several organizations and professional societies have released updated guidelines or consensus statements.

Join an expert panel of allergists and ear, nose, and throat specialists (ENTs) to discuss a multidisciplinary approach to the management of NPs. The panel will examine the place of biologics in NP care and encourage collaboration between ENTs and allergists to ensure effective care and improved outcomes for patients with NPs.

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:
  • Identify patient factors to predict relapse risk and determine candidacy for biologics
  • Discuss emerging models for interdisciplinary collaboration in the care of people with NPs

PHYSICIAN ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 30 minutes to complete.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

DISCLOSURES OF RELEVANT FINANCIAL RELATIONSHIPS

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global.  All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.  
All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:
Name of Faculty or Presenter Reported Financial Relationship
Eugenio De Corso, MD, PhD
Unit of Otorhinolaryngology
A Gemelli University Hospital Foundation 		Consulting Fee (e.g., Advisory Board): Sanofi, GSK, Novartis.
Speakers' Bureau: Sanofi, Astrazeneca, Novartis, GSK, Regeneron, Firma
Marco Caminati, MD
Asthma Center and Allergy Unit
Department of Medicine
University of Verona and Verona University Hospital
Italy 		Nothing to disclose

The planners and managers at Global Education Group have no relevant financial relationships to disclose.

The planners and managers at PlatformQ Health Education have no relevant financial relationships to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com

Technical Support:

For any technical issues or issues with your CME Certificate, please contact, ImmunologyLive, at 877-394-1306 or at Support@ImmunologyLive.com.